Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
qiliqiangxin
- Development stage
- Phase 4
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Qiliqiangxin is a standardized Traditional Chinese Medicine (TCM) formulation developed for the treatment of chronic heart failure (CHF). It is composed of 11 herbal ingredients, including *Astragalus membranaceus*, *Panax ginseng*, and *Salvia miltiorrhiza*. The drug exerts its therapeutic effects through a multi-target mechanism that includes inhibiting the renin-angiotensin-aldosterone system (RAAS), suppressing the sympathetic nervous system, improving myocardial energy metabolism, and reducing cardiac remodeling. Clinical evidence, most notably from the large-scale QUEST trial, has demonstrated that Qiliqiangxin significantly reduces the risk of hospitalization for heart failure and cardiovascular death when added to standard-of-care therapy in patients with heart failure and reduced ejection fraction (HFrEF). It is widely used in China and has been the subject of rigorous clinical evaluation to bridge the gap between traditional medicine and evidence-based cardiology.
- Brand names
- Qiliqiangxin
- Other names
- 芪苈强心胶囊Qiliqiangxin capsuleQLQX
02
Targets
PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)PPARG (Peroxisome proliferator-activated receptor gamma)RXRA (Retinoid X receptor alpha)AMPK (Adenosine monophosphate–activated protein kinase)ACE (Angiotensin Converting Enzyme)PPARA (Peroxisome proliferator-activated receptor alpha)TGFB1 (Transforming growth factor Beta-1 proprotein)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on qiliqiangxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on qiliqiangxin.